Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD044
MIFTS: 48

Bladder Disease

Categories: Nephrological diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bladder Disease

About this section

MalaCards integrated aliases for Bladder Disease:

Name: Bladder Disease 12 15 37 17
Urinary Bladder Diseases 43 71
Bladder Diseases 54 42
Urinary Bladder Disease 12

Classifications:

MalaCards categories:
Anatomical: Nephrological diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:365
ICD9CM 34 596.9
MeSH 43 D001745
NCIt 49 C2900
SNOMED-CT 67 42643001
UMLS 71 C0005686
Sources

Summaries for Bladder Disease

About this section
MedlinePlus : 42 The bladder is a hollow organ in your lower abdomen that stores urine. Many conditions can affect your bladder. Some common ones are Cystitis - inflammation of the bladder, often from an infection Urinary incontinence - loss of bladder control Overactive bladder - a condition in which the bladder squeezes urine out at the wrong time Interstitial cystitis - a chronic problem that causes bladder pain and frequent, urgent urination Bladder cancer Doctors diagnose bladder diseases using different tests. These include urine tests, x-rays, and an examination of the bladder wall with a scope called a cystoscope. Treatment depends on the cause of the problem. It may include medicines and, in severe cases, surgery. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bladder Disease, also known as urinary bladder diseases, is related to gallbladder disease and bladder cancer, and has symptoms including bladder fullness sensation An important gene associated with Bladder Disease is MIR199A1 (MicroRNA 199a-1), and among its related pathways/superpathways are MicroRNAs in cancer and SRF and miRs in Smooth Muscle Differentiation and Proliferation. The drugs Mirabegron and Rocuronium have been mentioned in the context of this disorder. Affiliated tissues include bladder, testes and kidney.

Disease Ontology : 12 A urinary system disease that is located in the bladder.

Sources

Related Diseases for Bladder Disease

About this section

Diseases related to Bladder Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 205)
# Related Disease Score Top Affiliating Genes
1 gallbladder disease 33.3 MIR205 MIR199A1 MIR17 MIR145 MIR143
2 bladder cancer 30.9 TERT MIR21 MIR205 MIR200A MIR199A1 MIR193A
3 biliary tract disease 30.5 MIR199A1 MIR17 MIR145 MIR139 H2AC18
4 bone inflammation disease 30.5 MIR675 MIR21 MIR199A1 MIR17 H2AC18
5 pancreatic cancer 30.3 TERT MIR21 MIR205 MIR200A MIR199A1 MIR17
6 colorectal cancer 30.1 TERT MIR675 MIR490 MIR21 MIR205 MIR200A
7 cystitis 11.3
8 diphyllobothriasis 10.9
9 thyroid gland follicular carcinoma 10.8 TERT MIR199A1 MIR17 MIR144
10 cervix small cell carcinoma 10.8 MIR199A1 MIR145 MIR143
11 esophagus adenocarcinoma 10.8 MIR21 MIR199A1 MIR145 MIR143
12 leukocyte disease 10.8 MIR21 MIR199A1 MIR17 MIR145 MIR144 H2AC18
13 pre-malignant neoplasm 10.8 MIR193A MIR17 MIR143 MIR139 H2AC18
14 gastrointestinal system benign neoplasm 10.8 MIR21 MIR199A1 MIR17 MIR143 MIR139 H2AC18
15 bile duct adenocarcinoma 10.8 MIR21 MIR199A1 MIR17 MIR145 H2AC18
16 in situ carcinoma 10.8 MIR193A MIR17 MIR143 MIR139 H2AC18
17 tongue disease 10.8 MIR21 MIR199A1 MIR193A MIR17 MIR145 MIR144
18 bone sarcoma 10.8 MIR21 MIR199A1 MIR193A MIR17 H2AC18
19 bile duct disease 10.8 MIR200A MIR199A1 MIR17 MIR145 MIR139 H2AC18
20 bone marrow cancer 10.8 MIR490 MIR21 MIR199A1 MIR17 MIR145 H2AC18
21 ovarian serous carcinoma 10.7 MIR21 MIR200A MIR199A1 MIR145 MIR143 MIR141
22 intestinal benign neoplasm 10.7 MIR21 MIR199A1 MIR17 MIR145 MIR143 MIR139
23 pleural cancer 10.7 MIR193A MIR17 MIR139 H2AC18
24 spinal disease 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR139 H2AC18
25 laryngeal disease 10.7 MIR490 MIR21 MIR17 MIR143 MIR139 H2AC18
26 retinal cancer 10.7 MIR675 MIR200A MIR199A1 MIR193A MIR17 H2AC18
27 ocular cancer 10.7 MIR675 MIR199A1 MIR193A MIR17 MIR143 H2AC18
28 autonomic nervous system neoplasm 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR103A1 H2AC18
29 peripheral nervous system neoplasm 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR103A1 H2AC18
30 pulmonary disease, chronic obstructive 10.7 TRPV1 MIR21 MIR199A1 MIR17 MIR144 H2AC18
31 aortic disease 10.7 MIR21 MIR205 MIR199A1 MIR17 MIR145
32 autosomal genetic disease 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR144 H2AC18
33 retinal vascular disease 10.7 MIR21 MIR199A1 MIR144 H2AC18
34 overnutrition 10.7 MIR21 MIR199A1 MIR17 MIR144 MIR103A1 H2AC18
35 inherited metabolic disorder 10.7 MIR21 MIR199A1 MIR17 MIR144 H2AC18
36 heart valve disease 10.7 MIR675 MIR21 MIR205 MIR199A1 MIR17 H2AC18
37 bone cancer 10.7 TRPV1 MIR21 MIR199A1 MIR193A MIR17 MIR145
38 central nervous system cancer 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR145 MIR144
39 larynx cancer 10.7 TERT MIR490 MIR21 MIR17 MIR143 MIR139
40 rectum cancer 10.7 MIR21 MIR200A MIR193A MIR17 MIR145 MIR143
41 endocrine organ benign neoplasm 10.7 MIR21 MIR199A1 MIR139 H2AC18
42 connective tissue cancer 10.7 MIR21 MIR199A1 MIR193A MIR17 MIR145 MIR144
43 diffuse large b-cell lymphoma 10.7 MIR21 MIR199A1 MIR17 MIR145 MIR143 MIR139
44 ovary epithelial cancer 10.7 MIR21 MIR200A MIR199A1 MIR193A MIR17 MIR145
45 cerebral arterial disease 10.7 MIR199A1 MIR145 MIR143
46 malignant ovarian surface epithelial-stromal neoplasm 10.7 MIR21 MIR200A MIR199A1 MIR193A MIR17 MIR145
47 disease of mental health 10.7 MIR21 MIR199A1 MIR17 MIR144 H2AC18
48 bile duct cancer 10.7 MIR21 MIR199A1 MIR17 MIR145 H2AC18
49 cell type benign neoplasm 10.7 MIR21 MIR200A MIR199A1 MIR17 MIR144 MIR143
50 lipid storage disease 10.7 MIR21 MIR199A1 MIR144 H2AC18

Comorbidity relations with Bladder Disease via Phenotypic Disease Network (PDN):


Acute Cystitis Bladder Neck Obstruction
Prostatic Hypertrophy

Graphical network of the top 20 diseases related to Bladder Disease:



Diseases related to Bladder Disease
Sources

Symptoms & Phenotypes for Bladder Disease

About this section

UMLS symptoms related to Bladder Disease:


bladder fullness sensation
Sources

Drugs & Therapeutics for Bladder Disease

About this section

Drugs for Bladder Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mirabegron Approved Phase 4 223673-61-8 9865528
2
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
3 Muscarinic Antagonists Phase 4
4 Adrenergic beta-Agonists Phase 4
5 Adrenergic Agents Phase 4
6 Cholinergic Agents Phase 4
7 Solifenacin succinate Phase 4 242478-38-2
8 Adrenergic Agonists Phase 4
9 Adrenergic beta-3 Receptor Agonists Phase 4
10 Cholinergic Antagonists Phase 4
11 Neurotransmitter Agents Phase 4
12 Neuromuscular Blocking Agents Phase 4
13 Anticonvulsants Phase 4
14 Bromides Phase 4
15 Pharmaceutical Solutions Phase 4
16
Chondroitin Phase 4 9007-27-6 53477707
17
Propiverine Approved, Investigational Phase 3 60569-19-9 4942
18
tannic acid Approved Phase 3 1401-55-4
19
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
20
Amitriptyline Approved Phase 3 50-48-6 2160
21
Perphenazine Approved Phase 3 58-39-9 4748
22
Adalimumab Approved Phase 3 331731-18-1 16219006
23
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
24
Midazolam Approved, Illicit Phase 3 59467-70-8 4192
25
Valrubicin Approved Phase 3 56124-62-0 41744
26 Tolterodine tartrate Phase 3 124937-52-6
27 abobotulinumtoxinA Phase 3
28 Botulinum Toxins, Type A Phase 3
29 Mitogens Phase 3
30 Botulinum Toxins Phase 3
31 Antidepressive Agents Phase 3
32 Analgesics, Non-Narcotic Phase 3
33 Psychotropic Drugs Phase 3
34 Antidepressive Agents, Tricyclic Phase 3
35 Analgesics Phase 3
36 Amitriptyline, perphenazine drug combination Phase 3
37 Antipsychotic Agents Phase 3
38 Anti-Inflammatory Agents Phase 3
39 Antirheumatic Agents Phase 3
40 Parasympatholytics Phase 3
41 Anti-Infective Agents Phase 3
42 Mandelic Acids Phase 3
43
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
44
Durvalumab Approved, Investigational Phase 2 1428935-60-7
45
Heparin Approved, Investigational Phase 2 9005-49-6 46507594 772
46
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
47
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
48
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
49
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
50
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124

Interventional clinical trials:

(show top 50) (show all 70)
# Name Status NCT ID Phase Drugs
1 Bladder Management in Patients With Multiple Sclerosis: Optimizing Practice Patterns Completed NCT01930799 Phase 4
2 The Effect of Deep Neuromuscular Blockade on Postoperative Shoulder Tip Pain After Laparoscopic Cholecystectomy Completed NCT02036827 Phase 4 Rocuronium
3 Efficacy and Safety of Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder Completed NCT03558919 Phase 4 Mirabegron 25mg;Solifenacin Succinate 5 MG
4 Prospective Randomised Trial Comparing Intravesical Chondroitin Sulphate 2% and DMSO in the Treatment of Painful Bladder Syndrome/ Interstitial Cystitis Terminated NCT04268810 Phase 4
5 A Double-Blind, Randomized Study of Puncturing Versus Non-Puncturing Acupuncture for the Treatment of Interstitial Cystitis Symptoms Unknown status NCT00094874 Phase 3
6 A Double-Blind, Randomized Study of the Safety and Efficacy of OnabotulinumtoxinA (OnaBoNT-A) Versus Oral Oxybutynin in Spinal Cord Injured Patients With Neurogenic Detrusor Overactivity (Protocol Number 11-09-10-04) Unknown status NCT01050114 Phase 3 onaBoNT-A;Oxybutynin ER
7 Efficacy and Tolerability of Propiverine Hydrochloride Extended Release (ER) Compared to Immediate Release (IR) in Patients With Neurogenic Detrusor Overactivity. A Randomized, Double Blind, Parallel Group, Multicenter Clinical Trial Completed NCT01530620 Phase 3 Propiverine hydrochloride ER (extended release);Propiverine hydrochloride IR (immediate release)
8 A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder Completed NCT01972841 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin succinate;Placebo to match mirabegron
9 A Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Subjects With Overactive Bladder (OAB) Treated With Antimuscarinics and Dissatisfied Due to Lack of Efficacy Completed NCT01638000 Phase 3 Mirabegron;Solifenacin succinate
10 A Randomized, Double-Blind, Multi-Centre Study to Evaluate the Efficacy and Safety of Adding Mirabegron to Solifenacin in Incontinent OAB Subjects Who Have Received Solifenacin for 4 Weeks and Warrant Additional Relief for Their OAB Symptoms Completed NCT01908829 Phase 3 mirabegron 25 mg;mirabegron 50 mg;solifenacin 5 mg;solifenacin 10 mg;mirabegron 25 mg matching placebo;mirabegron 50 mg matching placebo;solifenacin 5 mg matching placebo;solifenacin 10 mg matching placebo
11 A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder Completed NCT02045862 Phase 3 Solifenacin succinate;Mirabegron;Placebo to match solifenacin;Placebo to match mirabegron
12 A Randomized Multicenter Clinical Trial to Evaluate the Efficacy of Amitriptyline for the Treatment of Painful Bladder Syndrome (PBS) in Newly Diagnosed Patients Completed NCT00124306 Phase 3 Amitriptyline
13 An Investigator Initiated, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy of Humira® (Adalimumab) For The Treatment of Interstitial Cystitis(IC) Completed NCT01295814 Phase 3 Adalimumab
14 Oxybutynin for Post-surgical Bladder Pain and Urgency Recruiting NCT03952299 Phase 3 Oxybutynin Transdermal Patch;Oral Oxybutynin
15 A Randomized Controlled Study Comparing Adjuvant Hyperthermia Treatment in Conjunction With Mitomycin C Versus BCG Immunotherapy (BCG) Adjuvant Treatment in Patients With Superficial Transitional Cell Carcinoma of the Bladder (STCCB) Terminated NCT00384891 Phase 3 Bacillus Calmette-Guérin
16 A PHASE 3B, RANDOMIZED, OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MAINTENANCE THERAPY WITH VALRUBICIN VERSUS NO MAINTENANCE, IN SUBJECTS TREATED WITH VALRUBICIN INDUCTION FOR CARCINOMA IN SITU (CIS) OF THE BLADDER Terminated NCT01310803 Phase 3 VALSTAR - Maintenance Therapy
17 A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer Terminated NCT01200992 Phase 3
18 A Multi-Centre, Randomised, Open-Label Active-Controlled Study Comparing Safety and Efficacy of Synergo Radiofrequency (RF)-Induced Hyperthermia-Chemotherapy With Mitomycin C (RITE) Versus Bacillus Calmette-Guérin (BCG) as First-Line Treatment of Non-Muscle Invasive Papillary Bladder Cancer (NMIBC) Withdrawn NCT02254915 Phase 3 Bacillus Calmette-Guérin
19 A Randomized, Double-Blind, Factorial, Parallel-Group, Active and Placebo-Controlled, Multicenter Dose-Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Six Dose Combinations of Solifenacin Succinate and Mirabegron Compared to Mirabegron and Solifenacin Succinate Monotherapies in the Treatment of Overactive Bladder. Completed NCT01340027 Phase 2 Mirabegron;Solifenacin succinate;Placebo
20 A Phase II Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intravesical Alkalinized Lidocaine-Heparin for the Symptoms of Pelvic Pain and/or Urgency of Bladder Origin Completed NCT00256542 Phase 2 Alkalinized Lidocaine-Heparin
21 A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Adaptive, Combined Proof of Concept and Dose-Finding Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP3652 in the Treatment of Female Patients With Bladder Pain Syndrome / Interstitial Cystitis Completed NCT01613586 Phase 2 ASP3652;Placebo
22 Evaluation of the Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel Mixed With Mitomycin C (MMC) in Non-muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02307487 Phase 2 120 mg MMC in 90ml gel;140 mg MMC in 90ml gel;160 mg MMC in 90ml gel;120 mg MMC in 60ml gel;140 mg MMC in 60ml gel;160 mg MMC in 60ml gel
23 A Phase 1/2a Pilot Study of Intravesical TSD-001 for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer Recruiting NCT03081858 Phase 1, Phase 2 TSD-001
24 A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder Recruiting NCT02901548 Phase 2 Durvalumab
25 A Multi-centre Randomized, Placebo-controlled Trial of Mirabegron, a New beta3-adrenergic Receptor Agonist on Left Ventricular Mass and Diastolic Function in Patients With Structural Heart Disease Enrolling by invitation NCT02599480 Phase 2 mirabegron
26 A Multi-center, Double-blind, Randomized, Placebo-controlled, Cross-over Study to Evaluate the Efficacy, Safety and Tolerability of SAF312 in Subjects With Neurogenic Detrusor Overactivity Due to Spinal Cord Lesions Who Are Inadequately Managed by Antimuscarinic Therapy Terminated NCT01598103 Phase 2 SAF312;Placebo to SAF312
27 A Randomized Controlled Trial to Evaluate the Efficacy and Tolerability of Intravesical Cocktail and Comparison With Intravesical Dimethyl Sulfoxide (DMSO) for the Treatment of Painful Bladder Syndrome Including Interstitial Cystitis (PBS/IC) Terminated NCT00317070 Phase 2 dimethyl sulfoxide;IC Cocktail
28 A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects With Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy Terminated NCT02401542 Phase 1, Phase 2 Vofatamab;Docetaxel;Placebo
29 A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy, Safety, and Tolerability of JNJ-42160443 in Subjects With Interstitial Cystitis/ Painful Bladder Syndrome Terminated NCT01060254 Phase 2 Placebo;JNJ-42160443
30 A Multi-Center, Open-Label Phase 1b/2 Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy Terminated NCT03123055 Phase 1, Phase 2 B-701;Pembrolizumab
31 A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients With Selected Solid Tumors Completed NCT00753415 Phase 1
32 A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer Completed NCT02300610 Phase 1 Enzalutamide;Cisplatin;Gemcitabine
33 A Phase 1, Open-Label, Dose-Escalation and Expansion Study of IK-175, an Oral Aryl Hydrocarbon Receptor (AHR) Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Recruiting NCT04200963 Phase 1 IK-175
34 Gall Bladder Status Among Children With Chronic Haemolytic Anemia Attending to Assuit University Children Hospital Unknown status NCT03533322
35 Three-dimensional High-definition (3DHD) Laparoscopy Versus Two-dimensional High-definition (2DHD) Laparoscopy in Cholecystectomy: a Clinical Controlled Randomized Double Blinded Trial. Unknown status NCT02396927
36 Prospective Multicenter Human Randomized Controlled Evaluation of NOTES® Cholecystectomy Unknown status NCT01171027
37 A Multi Center Study to Obtain Bladder Tissue Specimens From Subjects Undergoing Transurethral Resection of Bladder Tumor (TURBT) or Other Transurethral Biopsy Procedures Completed NCT00615043
38 Bladder Endometriosis: Evaluation in MRI of the Involvement of the Posterior Inferior Wall Completed NCT03906760
39 A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of DrugTherapy for Overactive Bladder (OAB) Completed NCT02386072 mirabegron;antimuscarinic medication
40 The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation Completed NCT03591367
41 Non-Interventional Study Assessing Quality of Life, Treatment Satisfaction, Resource Utilisation, and Persistence With Treatment in Overactive Bladder (OAB) Patients Prescribed Betmiga® - A Multicenter Non-interventional Post Authorisation Study (PAS) Completed NCT02320773 Betmiga®
42 Biomechanical Assessment of Level Gait in Patient's Status Post Bladder Exstrophy Completed NCT00863070
43 Investigation of Falls and Balance of Patients With Parkinson's Disease With Urinary Disturbance Completed NCT03845725
44 Does Three-Dimensional Laparoscopy Provide Significant Advantages for Patients and Surgeons? A Randomised Controlled Trial Investigating Operating Time and Surgical Errors With 3D vs 2D Visual Systems in Laparoscopic Cholecystectomies. Completed NCT01930344
45 Evaluation of the Clinical Response of Mitomycin-C (MMC) Embedded in Hydrogel (TC-3) in Comparison to Mitomycin C in Saline, When Administered Intravesically, Pre-TURBT in Non Muscle Invasive Bladder Cancer (NMIBC) Patients. Muscle Invasive Bladder Cancer (NMIBC) Patients Completed NCT02891460
46 Heart Rate Variability in Patients With Neurogenic Detrusor Overactivity Before and After Botulinum Neurotoxin Type A Intradetrusor Injections Completed NCT01337024
47 Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment . Geriatric Oncology Protocol in Aquitaine Country. Completed NCT00210249
48 Prospective Comparative Multicenter Study on the Medico-economical Impact of the Brindley Technique in the Management of Neurogenic Bladder in Patients With Injured Spinal Cord Completed NCT00221767
49 Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) Completed NCT01803295
50 Effect of Pelvic Floor Muscle Training (PFMT) in Prevention and Treatment of Female Pelvic Organ Prolapse (POP). Completed NCT00271297

Search NIH Clinical Center for Bladder Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Acetic Acid
ACETIC ACID LIQUID
ACETIC ACID,GLACIAL LIQUID
Neostigmine
Neostigmine bromide
Neostigmine Methylsulfate
Propantheline
Propantheline Bromide
tolterodine
tolterodine tartrate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Disease:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Disease:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder diseases

Sources

Genetic Tests for Bladder Disease

About this section
Sources

Anatomical Context for Bladder Disease

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Disease:

19
Bladder

MalaCards organs/tissues related to Bladder Disease:

40
Testes, Kidney, Spinal Cord, Heart, Smooth Muscle, Prostate, Liver
Sources

Publications for Bladder Disease

About this section

Articles related to Bladder Disease:

(show top 50) (show all 631)
# Title Authors PMID Year
1
Effect of electroacupuncture on diabetic neurogenic bladder: A randomized controlled trial protocol. 42
32332636 2020
2
Evaluation and Treatment of Overactive Bladder in Women. 42
32029089 2020
3
Risk factors for mild depression in older women with overactive bladder syndrome-A cross sectional study. 42
31999718 2020
4
Differentiation potential of urothelium from patients with benign bladder dysfunction. 61 54
17537219 2007
5
Concentrations of specific epithelial growth factors in the urine of interstitial cystitis patients and controls. 61 54
9334654 1997
6
Re: Hypoxic Changes to the Urothelium as a Bystander of End-Stage Bladder Disease. 61
32073957 2020
7
Analysis of viruses present in urine from patients with interstitial cystitis. 61
32447589 2020
8
Detrusor bioengineering using a cell-enriched compressed collagen hydrogel. 61
32420687 2020
9
Increased expression of Psoriasin is correlated with poor prognosis of bladder transitional cell carcinoma by promoting invasion and proliferation. 61
31894335 2020
10
Increased expression of desmin and vimentin reduces bladder smooth muscle contractility via JNK2. 61
31909533 2020
11
Screening logs from a pilot randomized controlled trial of radical cystectomy versus chemoradiation therapy for muscle-invasive bladder cancer. 61
31676280 2020
12
A homozygous missense variant in CHRM3 associated with familial urinary bladder disease. 61
31441039 2019
13
Single-Cell Transcriptomic Map of the Human and Mouse Bladders. 61
31462402 2019
14
Revealing Associations between Diagnosis Patterns and Acupoint Prescriptions Using Medical Data Extracted from Case Reports. 61
31614636 2019
15
Three-Dimensional Reconstruction of Neurovascular Network in Whole Mount Preparations and Thick-Cut Transverse Sections of Mouse Urinary Bladder. 61
31496149 2019
16
Metastatic plasmacytoid bladder cancer causing malignant priapism. 61
31266754 2019
17
Augmentation Cystoplasty of Diseased Porcine Bladders with Bi-Layer Silk Fibroin Grafts. 61
30191762 2019
18
Hypoxic changes to the urothelium as a bystander of end-stage bladder disease. 61
30862459 2019
19
NF-κB and GATA-Binding Factor 6 Repress Transcription of Caveolins in Bladder Smooth Muscle Hypertrophy. 61
30707892 2019
20
Evidence-Based Guideline on Laparoscopy in Pregnancy: Commissioned by the British Society for Gynaecological Endoscopy (BSGE) Endorsed by the Royal College of Obstetricians & Gynaecologists (RCOG). 61
31695854 2019
21
Chronic Lower Urinary Tract Signs in Cats: Current Understanding of Pathophysiology and Management. 61
30736893 2019
22
Necessity of performing voiding cystourethrography for children with unilateral multicystic dysplastic kidney. 61
30255447 2019
23
Leiomyoma of the Retzius space in a male patient: A case report and a diagnostic approach to Retzius space diseases. 61
30374998 2019
24
Spontaneous cholecystopleural fistula leading to biliothorax and sepsis in a cat. 61
30792876 2019
25
Tissue Engineering in Pediatric Bladder Reconstruction-The Road to Success. 61
30984717 2019
26
Challenges To Attenuate Ureteric Stent-Related Symptoms: Reflections On The Need To Fashion A New Dynamic Stent Design Consequent Upon A Case Report. 61
31696096 2019
27
The Impact of Individual and Parental American Indian Boarding School Attendance on Chronic Physical Health of Northern Plains Tribes. 61
30431464 2019
28
Differentiation of Urothelium from Mouse Embryonic Stem Cells in Chemically Defined Conditions. 61
31273737 2019
29
A Randomized, Double-blind, Placebo-controlled Trial of Certolizumab Pegol in Women with Refractory Interstitial Cystitis/Bladder Pain Syndrome. 61
30072210 2018
30
Gall bladder mucoceles in Border terriers. 61
30079451 2018
31
Normal reference values for bladder wall thickness on CT in a healthy population. 61
29392368 2018
32
Therapeutic exploitation of IPSE, a urogenital parasite-derived host modulatory protein, for chemotherapy-induced hemorrhagic cystitis. 61
29613835 2018
33
Bladder and Ureteral Dysfunction Leading to Hydronephrosis and Hydroureteronephrosis in Adults. 61
29287975 2018
34
Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease. 61
30105760 2018
35
Contrast-enhanced ultrasound complements two-dimensional ultrasonography in diagnosing gallbladder diseases in dogs. 61
29393556 2018
36
Underlying Chronic Disease, Medication Use, History of Running Injuries and Being a More Experienced Runner Are Independent Factors Associated With Exercise-Associated Muscle Cramping: A Cross-Sectional Study in 15778 Distance Runners. 61
28901963 2018
37
Bladder Leiomyosarcoma 25 Years after Treatment with Cyclophosphamide in Patient with History of Retinoblastoma. 61
26675030 2018
38
In Vitro Differentiation and Propagation of Urothelium from Pluripotent Stem Cell Lines. 61
28889383 2018
39
Asymptomatic solitary bladder plasmocytoma: A case report and literature review. 61
29390408 2017
40
Medical comorbidity in polycystic ovary syndrome with special focus on cardiometabolic, autoimmune, hepatic and cancer diseases: an updated review. 61
28901968 2017
41
Emergency Department Utilization in Patients With Neurogenic Bladder: Contemporary Burden and National Trends in Prevalence, Inpatient Admission, and Associated Charges, 2006-2011. 61
28755964 2017
42
Antiproliferative factor (APF) binds specifically to sites within the cytoskeleton-associated protein 4 (CKAP4) extracellular domain. 61
28893174 2017
43
Cystic duct pressures after ligation with a novel absorbable device in an ex vivo caprine cholecystectomy model. 61
28725113 2017
44
Management of Neurogenic Bladder. 61
28553689 2017
45
Long-term Outcomes of Augmentation Enterocystoplasty in Patients With End-Stage Bladder Diseases: A Single-Institute Experience Involving 102 Patients. 61
28673062 2017
46
Effect of ultrasonography surveillance in patients with liver cancer: a population-based longitudinal study. 61
28645973 2017
47
Primary amyloidosis of the bladder; a mimicker of bladder cancer. 61
28646945 2017
48
Urinary excretion of EGF and MCP-1 in children with vesicoureteral reflux. 61
28191787 2017
49
Study on the Relation between Colorectal Cancer and Gall Bladder Disease. 61
28511430 2017
50
Cigarette smoke-induced urothelial cell damage: potential role of platelet-activating factor. 61
28270596 2017
Sources

Variations for Bladder Disease

About this section
Sources

Expression for Bladder Disease

About this section
Search GEO for disease gene expression data for Bladder Disease.
Sources

Pathways for Bladder Disease

About this section

Pathways related to Bladder Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.77 MIR21 MIR205 MIR200A MIR199A1 MIR17 MIR145
2
SRF and miRs in Smooth Muscle Differentiation and Proliferation 1
10.07 MIR199A1 MIR145
Sources

GO Terms for Bladder Disease

About this section

Cellular components related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.32 MIR21 MIR205 MIR199A1 MIR17 MIR144 MIR143
2 extracellular vesicle GO:1903561 9.26 MIR21 MIR193A MIR17 MIR103A1

Biological processes related to Bladder Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.9 TERT MIR21 MIR17 MIR144
2 positive regulation of protein kinase B signaling GO:0051897 9.85 MIR21 MIR199A1 MIR143 HBEGF
3 positive regulation of angiogenesis GO:0045766 9.81 TERT MIR21 MIR199A1 MIR143
4 negative regulation of angiogenesis GO:0016525 9.76 MIR21 MIR193A MIR145 MIR143
5 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.71 TERT MIR21 MIR17
6 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.65 MIR21 MIR199A1 MIR145
7 negative regulation of cardiac muscle hypertrophy GO:0010614 9.62 MIR21 MIR145
8 regulation of smooth muscle contraction GO:0006940 9.61 MIR145 MIR143
9 negative regulation of glucose import GO:0046325 9.61 MIR143 MIR103A1
10 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.59 MIR199A1 MIR17
11 negative regulation of systemic arterial blood pressure GO:0003085 9.58 TRPV1 MIR17
12 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.58 MIR199A1 MIR17
13 angiotensin-activated signaling pathway GO:0038166 9.57 MIR145 MIR143
14 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.56 MIR21 MIR17
15 negative regulation of vascular endothelial growth factor production GO:1904046 9.54 MIR205 MIR199A1 MIR17
16 aorta smooth muscle tissue morphogenesis GO:0060414 9.52 MIR145 MIR143
17 regulation of phenotypic switching GO:1900239 9.49 MIR145 MIR143
18 gene silencing by miRNA GO:0035195 9.47 MIR675 MIR490 MIR21 MIR205 MIR200A MIR199A1
19 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.43 MIR17 MIR143
20 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.43 TERT MIR21 MIR143
21 positive regulation of vascular smooth muscle contraction GO:1904695 9.4 MIR21 CHRM3
22 miRNA mediated inhibition of translation GO:0035278 9.35 MIR21 MIR205 MIR17 MIR145 MIR103A1
23 positive regulation of metalloendopeptidase activity GO:1904685 9.33 MIR21 MIR205 MIR17
24 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.32 MIR145 MIR143

Molecular functions related to Bladder Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.4 MIR675 MIR21 MIR205 MIR200A MIR199A1 MIR193A
Sources

Sources for Bladder Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....